scholarly journals Role of Behavioral Activation and Inhibition Systems in Symptoms of Major Depression Disorder Regarding the Mediating Role of Cognitive Bias

2020 ◽  
pp. 215-221

Background: This study aimed to investigate the role of the behavioral activation and inhibition systems in symptoms of major depressive disorder, considering the mediating role of cognitive bias. Materials and Methods: The statistical population of this descriptive-correlational research was all the students of Ahvaz Azad University, Ahvaz, Iran during the academic year 2015-16. In total, 300 students were selected using the multistage sampling method, and finally, 279 students participated in this research. Data were collected using the Behavioral Inhibition/Activation Systems Scale, the Dysfunctional Attitudes Scale, and the Beck Depression Inventory. The collected data were analyzed using multiple regression analysis, coefficient correlation, and structural equation modeling in SPSS (version 22), Lisrel (version 8.80), and Mplus (version 6.12) software. Results: The results showed that cognitive bias mediated the influence of behavioral inhibition and activation systems on depressive disorder. Based on the findings, all of the direct and indirect effects of the model were significant. The model itself had a suitable index of fit, and cognitive bias significantly affected major depressive disorder symptoms. In the final model, the direct effect of the behavioral inhibition system was added to depression. Moreover, the indirect effect of the behavioral activation system on depression was not significant. Conclusion: The proposed model had an acceptable fitness to the result and was an essential step in recognition of the significant factors of major depressive disorder. It can be useful as a model for designing stress management programs and decreasing major depression disorder.

Author(s):  
Priya Vishal Naik ◽  
Prachi Datta Dalvi U.

The WHO theme for the year 2017 is Depression. Depression (major depressive disorder) is a common and serious medical illness that negatively affects how a person feels, thinks and behaves. Psychotherapy if incorporated along with medications can be of substantial help in depression. It is also called ‘talking therapy’ and is based on personal interaction with the patient. Patients suffering from this disorder do not easily accept it and hence do not feel the need to seek medical intervention or counselling. In this process the symptoms might get aggravated and suicidal tendency (which is the worst effect of this disease) may develop. So it is extremely essential for the patient, family and society to accept, talk, discuss and seek treatment for this disease. This ‘talking therapy’ is of utmost importance in today’s life where concept of privacy is taking its toll. This therapy is mentioned in Ayurveda as Aashwasan Chikitsa. Aashwasan Chikitsa consists of good, pleasing and benevolent thoughts, spiritual ideas, positive attitude, ethics and communication with near ones. So in the treatment of psychological disorders, along with medications counselling therapy plays a very important role. Finally counselling can act as a part of preventive, curative therapy and also aids to avoid recurrence in the patients of depression.


2020 ◽  
Author(s):  
Samuel David Clark

AbstractThe kappa opioid receptor (KOR) and its endogenous ligands dynorphins (DYN) have been implicated in the development or symptomatology of a variety of neuropsychiatric disorders. This review covers a brief history of the development of KOR agonists and antagonists, their effects in healthy volunteers, and the potential role of DYN/KOR dysfunction in schizophrenia and major depressive disorder from a translational perspective. The potential role of DYN/KOR dysfunction in schizophrenia is based on several lines of evidence. Selective KOR agonists induce affective states in healthy volunteers with similarities to the symptoms of schizophrenia. Studies have shown increased DYN in patients with schizophrenia, although the data have been mixed. Finally, meta-analytic data have shown that opioid antagonists are associated with reductions in the symptoms of schizophrenia. The potential role of DYN/KOR dysfunction in major depressive disorder is also based on a combination of preclinical and clinical data. Selective KOR agonists have shown pro-depressive effects in human volunteers, while selective KOR antagonists have shown robust efficacy in several preclinical models of antidepressant activity. Small studies have shown that nonselective KOR antagonists may have efficacy in treatment-resistant depression. Additionally, recent clinical data have shown that the KOR may be an effective target for treating anhedonia, a finding relevant to both schizophrenia and depression. Finally, recommendations are provided for translating preclinical models for schizophrenia and major depressive disorder into the clinic.


2013 ◽  
Vol 37 (8) ◽  
pp. 1336-1345 ◽  
Author(s):  
Sandra Odebrecht Vargas Nunes ◽  
Heber Odebrecht Vargas ◽  
Eduardo Prado ◽  
Decio Sabbatini Barbosa ◽  
Luiz Picoli de Melo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document